SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(5 sites)

United Kingdom

Western General Hospital, Edinburgh, Scotland

The Royal Marsden NHS Foundation Trust, Sutton, Surrey

University College London Hospitals, London, UK

The Royal Marsden NHS Foundation Trust, London

The Christie NHS Foundation Trust, Manchester